Abstract: Deuterated forms of idazoxan according to Formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treatment or prevention using these compounds or pharmaceutical compositions are described. The compounds are useful for treating or preventing a disease or condition selected from psychosis, schizophrenia, schizoaffective disorder, Parkinson's disease, Lewy body dementia, sleep disorder (including insomnia), agitation, mood disorder (including depression), thromboembolic disorder, autism, and attention deficit hyperactivity disorder.

Abstract: The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.

Abstract: The present invention pertains to inherently flame-resistant, partially aromatic polyamides comprising the polyamide units AB/AC/AE/DB/DC/DE/F, characterized in that, in addition to the polyamide units AC, at least one further polyamide unit is selected from the group consisting of the polyamide units AB, AE, DB, DC, DE and F, the monomer units A, B, C, D, E and F being derived from the following molecules which are present amidically bonded in the polyamide X: A: aliphatic diamines; B: aromatic phosphorus-free dicarboxylic acids; C: phosphorus-containing, aromatic dicarboxylic acids according to formula 1, 2 and/or 3 D: Diamines with aromatic structural units; E: aliphatic dicarboxylic acids F: aminocarboxylic acids, lactams. The invention also pertains to flame-retardant molding compounds based on the flame-retardant polyamides and to molded parts formed from the polyamides or polyamide molding compounds according to the invention.

Abstract: Certain aspects of the present disclosure include compounds having Formula (X). Disclosed embodiments also include compositions comprising at least one compound according to the present disclosure, such as from 5% to 70% of at least one compound according to the present disclosure, at a dosage of from 0.1 mg to about 10,000 mg, and further comprising an excipient, an adjuvant, a carrier, and/or at least one additional biologically active compound other than a compound according to the present disclosure. Disclosed compounds and/or can be administered to a subject multiple times per day, such as 1 to 3 times per day, and/or periodically, such as every 2 to 7 days, for a variety of reasons, such as to increase neuronal plasticity, to treat a neurological disease, to treat a neuropsychiatric disease, to elicit a biological response, such as by activating a 5-HT2A receptor, or to increase at least one of translation, transcription, or secretion of neurotrophic factors.

Abstract: The present disclosure relates to compounds Formula (I): methods for making the compounds and methods for their use.

Abstract: Disclosed herein are 2-bromo-LSD analogs of Formula (I) or a pharmaceutically acceptable salt thereof, as well as methods for making and using the compounds to, for example, treat neuropsychiatric disorders.

Abstract: Disclosed herein are xanomeline analogs, as well as methods for making and using the analogs to, for example, treat neuropsychiatric disorders.

Abstract: Disclosed herein are isotopically enriched compounds of 2-bromolysergic acid diethylamide, LSD, ALD-52, and 1P-LSD, as well as methods for their use in treating neurologic and brain disorders.

Abstract: Disclosed herein are salt and solid forms of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine. The solid form may be a salt and/or a crystalline form of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine, such as a polymorph of N-eth-yl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a salt thereof. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The solid forms of V-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Disclosed herein are salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate (4-OH-DIPT), e.g., 4-OH-DIPT hemi-glutarate, 4-OH-DIPT hemi-succinate, 4-OH-DIPT hemi-succinate hydrochloride, and 4-OH-DIPT hemi-glutarate hydrochloride. The solid form may be a salt and/or a crystalline form of the 4-OH-DIPT, such as a polymorph of 4-OH-DIPT or a salt thereof. Also disclosed are methods for making the solid forms and methods for administering the solid forms. The disclosed solid forms of 4-OH-DIPT are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Described herein are isotopically enriched analogs of methylone (e.g., deuterated analogs of methylone (e.g., (S)-methylone and (R)-methylone) with improved characteristics. Also described herein are salts (such as hydrochloride salt) and solid forms (e.g., crystalline forms) of methylone. Also described herein are stereoisomers (e.g., enantiomers) of methylone. The present disclosure also provides methods of making and methods of use of the methylone or methylone analogs and solid forms of 3,4-methylenedioxy-N-ethylcathinone hydrochloride described herein to treat brain and neurological disorders such as depression.

Abstract: The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.

Abstract: Disclosed herein are isotopically enriched compounds and methods of using both isotopically and non-isotopically enriched compounds of the following formula in the treatment of neurologic and brain disorders/conditions.

Abstract: Disclosed herein are salts and solid state forms of psilocybin, including psilocybin HCl, and salts and solid forms of O-acetylpsilocin, including O-acetylpsilocin fumarate. Also disclosed are methods for making the salts and solid forms and methods for administering the salts and solid forms. The salts and solid forms disclosed herein are useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.

Abstract: Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and/or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and/or a psychiatric disorder in a subject.

Abstract: Deuterium-containing analogs/derivatives of N,N,N-trimethyl-4-phosphoryloxytryptamine are disclosed. The deuterated compounds can be incorporated into pharmaceutical compositions and used to treat diseases such as psychological diseases and disorders.

Abstract: The subject matter of this disclosure relates to systems and methods for monitoring and managing machine learning models and related data. Histogram structures can be used to aggregate streams of numerical data for storage and metric calculations. Drift in such data can be identified and monitored over time. When significant drift is detected and/or when model accuracy has deteriorated, models can be automatically refreshed with updated training data and/or replaced with one or more other models. A model controller is used to automate model monitoring and management activities across multiple prediction environments where models are deployed and prediction jobs are executed.

Abstract: Disclosed herein are xanomeline analogs, as well as methods for making and using the analogs to, for example, treat neuropsychiatric disorders.

Abstract: Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and/or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and/or a psychiatric disorder in a subject.